Mesoblast Surpasses $100M in Ryoncil Sales, Boosting Cell‑Therapy Growth
Mesoblast’s Ryoncil cell therapy hits $100 M+ in sales, boosting revenue and fueling expansion into new diseases, back‑pain, and heart failure treatments.
2 minutes to read
MESOBLAST LTD
JPMorgan Gains 5% Stake in Mesoblast, Boosting Investor Confidence
JPMorgan Chase now owns 5% of Melbourne‑based Mesoblast, the biotech firm focused on cardiovascular and cancer drugs, and its stock is trading at AUD 2.06 with a $1.73B market cap.
2 minutes to read
JPMorgan Joins Mesoblast, Boosting Investor Confidence in Australia’s Biotech Leader
Discover how JPMorgan’s 5% stake in Mesoblast Limited could impact the biotech firm’s growth, drug development and investor confidence.
3 minutes to read
Mesoblast’s Stem‑Cell Breakthroughs Spark Pharma Interest, Boosting Future Valuation
Mesoblast Limited, a Melbourne‑based biotech pioneer, is advancing stem‑cell therapies across cardiovascular, oncology, hematology, and orthopedics, attracting major pharma interest while navigating financial challenges and a fluctuating ASX valuati…
2 minutes to read
Mesoblast: Australian Biotech Leader Poised for Regenerative Medicine Growth
Explore Mesoblast Limited’s cutting‑edge regenerative therapies, its ASX stock dynamics, and future growth prospects for investors and biotech professionals.
2 minutes to read
Mesoblast Celebrates FDA Approval and Launch of Ryoncil® as a Milestone in Cellular Medicine
Mesoblast Limited, a biotechnology company, has announced its financial results and operational updates, highlighting the successful FDA approval and commercial launch of its product Ryoncil, a treatment for steroid-refractory acute graft-versus-hos…
3 minutes to read